Abstract
Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Current Enzyme Inhibition
Title: Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Volume: 7 Issue: 2
Author(s): Kalyan K. Sethi, Padilam Suresh and Sumanta Mondal
Affiliation:
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Abstract: Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Export Options
About this article
Cite this article as:
K. Sethi Kalyan, Suresh Padilam and Mondal Sumanta, Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius, Current Enzyme Inhibition 2011; 7 (2) . https://dx.doi.org/10.2174/157340811796575272
DOI https://dx.doi.org/10.2174/157340811796575272 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Can Topiramate Induce Pruritus? A Case Report and Review of Literature
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Current Pharmaceutical Design Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice
CNS & Neurological Disorders - Drug Targets Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Involvement of microRNA-146a in the Inflammatory Response of S tatus Epilepticus Rats
CNS & Neurological Disorders - Drug Targets Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Neuromodulation of Hippocampal Synaptic Plasticity, Learning, and Memory by Noradrenaline
Central Nervous System Agents in Medicinal Chemistry Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders
CNS & Neurological Disorders - Drug Targets The GABA A Receptor Subunits Heterologously Expressed in Xenopus Oocytes
Mini-Reviews in Medicinal Chemistry In-vitro Antioxidant activity of ‘Aswathy Chooranam’- a Siddha Drug
Current Traditional Medicine AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy